[1] ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209.
[2] GEISLER CE, RENQUIST BJ. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones. J Endocrinol. 2017;234(1):R1-R21.
[3] AKBAR S, PINCON A, LANHERS MC, et al. Expression profile of hepatic genes related to lipid homeostasis in LSR heterozygous mice contributes to their increased response to high-fat diet. Physiol Genomics. 2016;48(12):928-935.
[4] RINELLA ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015; 313(22):2263-2273.
[5] CHIANG JYL, FERRELL JM. Bile Acid Metabolism in Liver Pathobiology. Gene Expr. 2018;18(2):71-87.
[6] CHIANG JYL. Bile acid metabolism and signaling. Compr Physiol. 2013;3(3):1191-1212.
[7] LEFEBVRE P, CARIOU B, LIEN F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89(1):147-191.
[8] KUNDU S, KUMAR S. Cross-talk between bile acids and gastrointestinal tract for progression and development of cancer and its therapeutic implications. IUBMB Life. 2015;67(7):514-523.
[9] IBTAHIM SH, HIRSOVA P, MALHI H, et al. Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Dig Dis Sci. 2016;61(5):1325-1336.
[10] YANG L, XIONG AZ, HE YQ, et al. Bile acids metabonomics study on the CCl4 and alpha-naphthylisothiocyanate-induced animal models: quantitative analysis of 22 bile acids by ultraperformance liquid chromatography-mass spectrometry. Chem Res Toxicol. 2008;21(12):2280-2288.
[11] ANSTEE QM. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87(1):1-16.
[12] GYAMFI MA, DAMJANOV I, FRENCH S, et al. The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochem Pharmacol. 2008;75(4):981-995.
[13] LAU JK, ZHANG X. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol. 2017;241(1):36-44.
[14] YAMADA T, OBATA A, KASHIWAGI Y, et al. Gd-EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice. Magn Reson Imaging. 2016;34(6):724-729.
[15] 范建高,王国良.脂肪肝与肝纤维化[J].肝脏,1999,4(2):3-5.
[16] SUN R, YANG N, KONG B, et al. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway. Mol Pharmacol. 2017;91(2):110-122.
[17] JIA W, XIE G. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15(2):111-128.
[18] CHIANG JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol. 2004;40(3):539-551.
[19] CHOW MD, LEE YH. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med. 2017;56:34-44.
[20] JONES H, ALPINI G. Bile acid signaling and biliary functions. Acta Pharm Sin B. 2015;5(2):123-128.
[21] 张久聪, 聂青和. 胆汁酸代谢及相关进展[J]. 胃肠病学和肝病学杂志,2008, 17(11): 953-956.
[22] HOFMANN AF, HAGEY LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci. 2008;65(16):2461-2483.
[23] 黄延风, 朱朝敏. 胆汁酸的毒性作用[J]. 国际检验医学杂志,2006,27(2): 152-153+157.
[24] THOMAS C, PELLICCIARI R, PRUZANSKI M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008;7(8):678-693.
[25] MONTE MJ, MARIN JJ, ANTELO A, et al. Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol. 2009;15(7):804-816.
[26] XIE G, WANG X, HUANG F, et al. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer. 2016;139(8):1764-1775.
[27] LU Y, DU Y, QIN L, et al. Gypenosides Altered Hepatic Bile Acids Homeostasis in Mice Treated with High Fat Diet. Evid Based Complement Alternat Med. 2018;2018:8098059. |